Article

Genetic Profiles in Pharmacogenes Indicate Personalized Drug Therapy for COVID-19

2020-03-30

Abstract excerpt

<h4>Background</h4> The coronavirus disease 2019 (COVID-19) has become a global pandemic currently. Many drugs showed potential for COVID-19 therapy. However, genetic factors which can lead to different drug efficiency and toxicity among populations are still undisclosed in COVID-19 therapy. <h4>Methods</h4> We selected 67 potential drugs for COVID-19 therapy (DCTs) from clinical guideline and clinical trials data...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: ea2bde9d-ac90-5cf4-884a-10453ff3e2cb
DOI: 10.1101/2020.03.23.20041350

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Genetic Profiles in Pharmacogenes Indicate Personalized Drug Therapy for COVID-19DOI 10.1101/2020.03.23.20041350Read

Pharmacogenetics Approach for the Improvement of COVID-19 TreatmentSemantic proximity Read

Pharmacogenomic landscape of COVID-19 therapies from Indian population genomes.Semantic proximity Read

Pharmacogenomics to Drive COVID-19 Therapy for Best Outcome in a Low Resource SettingSemantic proximity Read

Pharmacogenomic Study of SARS-CoV-2 Treatments: Identifying Polymorphisms Associated with Treatment Response in COVID-19 PatientsSemantic proximity Read

In silico Drug Repurposing to combat COVID-19 based on Pharmacogenomics of Patient Transcriptomic DataSemantic proximity Read

Exploring drugs and vaccines associated with altered risks and severity of COVID-19: a UK Biobank cohort study of all ATC level-4 drug categoriesSemantic proximity Read

Assessing ADME gene coverage: An observational study on chloroquine therapy for COVID-19.Semantic proximity Read

Coverage Rate of ADME Genes: Application to CYP2C8, CYP2D6 and CYP3A Genes for Personalized Chloroquine Treatment Against CoronavirusSemantic proximity Read

Drug-utilisation Profiles and COVID-19: Retrospective Cohort Study in ItalySemantic proximity Read

Association of Pharmacogenomic Phenotypes in CYP2D6, CYP2C9, CYP2C19, and CYP3A5 on Polypharmacy in Veterans.Semantic proximity Read

Pharmacogenomic and drug interaction risk associations with hospital length of stay among Medicare Advantage members with COVID-19Semantic proximity Read

Computational Determination of Toxicity Risks Associated with a Selection of Approved Drugs having Demonstrated Activity Against COVID- 19Semantic proximity Read